Geneoscopy said the updated CMS coverage determination for colorectal cancer screening provides a pathway that supports future RNA-based stool assays. The company positioned the decision as a “forward-thinking” framework for high-sensitivity molecular tests and indicated the change ensures Medicare beneficiaries have timely access to screening technologies that secure FDA approval. The company reiterated performance metrics for ColoSense and linked the coverage to guideline adoption, noting the test is included in NCCN and American Cancer Society guidance with a recommended three-year interval. It also reiterated its collaboration with Labcorp to expand access through the lab’s network. While this is a single regulatory update, the editorial focus is on reimbursement mechanics: national coverage policy can change ordering patterns, lab contracts, and commercialization velocity for molecular screening. Industry takeaway: RNA-based screening is moving closer to mainstream adoption as payor coverage aligns with FDA-approved performance claims.